



Radius Health, Inc.  
Investor Relations Department  
950 Winter St, North Building 1st Floor  
North Building 1st Floor  
Waltham, MA 02451  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: RDUS

|               |                            |
|---------------|----------------------------|
| Last Trade:   | 29.46                      |
| Trade Time:   | 1:22 PM ET<br>May 22, 2018 |
| Change:       | 0.45  (+1.551%)            |
| Day Range     | 28.25 - 29.68              |
| 52-Week Range | 24.66 - 49.16              |
| Volume        | 620,689                    |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOS<sup>®</sup> (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch f... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- May 11, 2018*  
[Radius Health to Present at the Bank of America Merrill Lynch 2018 Annual Healthcare Conference](#)
- May 10, 2018*  
[Radius Health Reports First Quarter 2018 Financial and Operating Results and Provides Business Update](#)
- Apr 24, 2018*  
[Radius Health to Announce First Quarter 2018 Financial Results, Host Conference Call and Live Webcast on May 10, 2018](#)
- Mar 30, 2018*  
[Radius Health Initiates Phase 3 Clinical Trial of Abaloparatide Injection for the Treatment of Male Osteoporosis](#)
- Mar 22, 2018*  
[Radius Health Provides Update on CHMP Opinion for Abaloparatide-SC](#)

## Financials [\[ View all \]](#)

- [First Quarter Financial Results](#)
- Mar 1, 2018*  
[Annual Report \(10-K\)](#)
- Apr 20, 2018*  
[Proxy Statement \(DEF 14A\)](#)
- May 10, 2018*  
[Quarterly Report \(10-Q\)](#)
- Nov 2, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2017*  
[Quarterly Report \(10-Q\)](#)